Sign inJoin waitlistJoin the waitlist

Charles Leath

Ellen Gregg Shook Culverhouse Chair in Gynecologic Oncology · University of Alabama Hospital

Credentials: · · · · · · ·

History

University of Alabama Hospital
Present

The University of Alabama
2003–2006
Obstetrics and Gynecology
University of Alabama at Birmingham Marnix E. Heersink School of Medicine
1999–2003
Med Univ of South Carolina Coll of Med
1994–1998

Research

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
New England Journal of Medicine · 2019 · 726 citations
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
New England Journal of Medicine · 2023 · 633 citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations

Michael Straughn
50 papers · 19 as a resident
Warner Huh
42 papers · 11 as a fellow
Ronald Alvarez
31 papers
Rebecca Arend
20 papers · 6 as a fellow
Teresa Boitano
18 papers · 10 as a resident
Haller Smith
17 papers · 10 as a resident
NP
Neil Phippen
16 papers · 11 as a resident
Britt Erickson
14 papers · 7 as a fellow
Rodney Rocconi
14 papers · 9 as a resident
Jason Barnett
12 papers · 8 as a fellow
MB
Mack Barnes
12 papers · 1 as a fellow
Larry Kilgore
11 papers

Grants

NCTN Deep South Research Consortium
National Cancer Institute · UG1
Contact PI · $3.7M · University of Alabama at Birmingham
2019–2032
Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $1.8M · University of Alabama at Birmingham
1997–2027
NCTN Deep South Research Consortium
National Cancer Institute · U10
Contact PI · $1.4M · University of Alabama at Birmingham
2014–2019

Clinical trials

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
Principal investigator · Active not recruiting · Phase 3
National Cancer Institute (NCI)
2016–2027
Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer
Principal investigator · Completed · Phase 1
University of Alabama at Birmingham
2014–2017
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients
Site PI · Recruiting · Phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2025–2030